The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer

No Standard therapy has been approved for third‐line therapy of advanced pancreatic cancer. K001 is peptidoglycan prepared from the marine microorganism, with an anti‐tumor activity. Previously, the phase I study of K001 has shown that K001 was safety and had some effectiveness for pancreatic patients. Now, we would like to lunch a randomized, blinded, parallel‐controlled, multi‐center phase II/III study to compare the best support care (BSC) plus K‐001 versus BSC plus placebo for the third‐line and later treatment of patients with advanced pancreatic cancer.